Friday, March 2, 2007

7:30 am–9:30 amNew Frontiers in Interventional Oncology:Diagnosis, Treatment, and EvaluatingResponse (PL)Room: 6ABC

Coordinator/Moderator: William S. Rilling, MD

Objectives—At the end of this session, thelearner should be able to:

1. Review the role of immunotherapy and biolog-ically active devices in cancer therapy

2. Relate current and future goals of molecularimaging and therapies for cancer

3. Illustrate the role of new technologies for imagefusion and robotic guidance

4. Assess treatment outcomes for regional cancertherapy

7:30 amGold Medal Award PresentationEugene Klatte, MD

7:45 amMolecular ImagingMichael D. Kuo, MD

8:00 amNew Guidance Techniques I: Fusion ImagingBradford Johns Wood, MD

8:10 amNew Guidance Techniques II: RoboticsStephen B. Solomon, MD

8:20 amBiologically Active Devices in Cancer TherapyLindsay Machan, MD

8:30 amDrug Eluting BeadsKaterina Malagari, MD

8:40 amNew Drugs for TACE and ImmunotherapyKevin L. Sullivan, MD

8:50 amTargeting Tumor Metabolism With Intra-ArterialTherapyJeff H. Geschwind, MD

9:00 amNew Ablation Modalities: MicrowaveFred T. Lee, MD

9:05 amNew Ablation Modalities: ElectroporationTBD

9:10 amNew Ablation Modalities: HIFUTBD

9:15 amMoving Beyond RECIST: PET, Multi-ParametricMRI for Evaluating Tumor ResponseIham Kamel, MD

10:00 am–12:00 pmFibroid Therapies: Who, How, and WhatAbout After (CC)Room: 6E

Coordinator/Moderator: Gary P. Siskin, MD

Objectives—At the end of this session, thelearner should be able to:

1. Describe pre-procedure evaluation and patientselection criteria prior to UAE

2. Apply the use of UAE in patients with a desire topreserve fertility options after the procedure

3. Demonstrate the imaging evaluation of patientsbefore and after UAE

4. Discuss the results and issues surrounding thedifferent embolic agents utilized for UAE

5. Assess the most recent data regarding UAE per-formed for patients with symptomatic uterinefibroids

6. Identify the potential complications after UAE7. Employ appropriate evaluation and manage-

ment of these patients

10:00 amClinical Evaluation/Patient SelectionGary P. Siskin, MD

10:15 amDEBATE: Treating the Infertile PatientKeith Issacson,Jean-Pierre Pelage, MD, PhD

10:27 amPre- and Post-Procedure ImagingSusan Ascher, MD

10:42 amDEBATE: Embolic Agent SelectionJafar Golzarian, MDRichard Shlansky-Goldberg, MD

10:57 amPost-Procedure Evaluation I: Short-TermChieh-Min Fan, MD

11:12 amPost-Procedure Evaluation II: Long-TermJean-Pierre Pelage, MD, PhD

11:27 amUpdate on HIFUGina K. Hesley, MD

P2

11:42 amQ&A

10:00 am–12:00 pmUnderstanding the Clinical Issues ofThoracic Aortic Disease (CC)Room: 2AB

Coordinator/Moderator: Michael D. Dake, MD

Objectives—At the end of this session, thelearner should be able to:

1. Distinguish the clinical manifestations of tho-racic aortic lesions that dictate intervention

2. Formulate a plan to determine what interven-tional management option is best for an individ-ual patient with thoracic aortic disease

3. Distinguish the relative risks and benefits ofendovascular intervention compared with thoseof medical therapy or surgical intervention for avariety of aortic pathologies and underlying pa-tient conditions

4. Anticipate complications of thoracic aortic dis-ease processes and predict which patients are atincreased risk of complications related to thenatural history of their disease and/or the inter-ventional management strategy selected

10:00 amIntroductionMichael D. Dake, MD

10:02 amThoracic Aortic Aneurysms: What Are thePathophysiology, Natural History, and Range ofDisease Expression?John Elefteriades, MD

10:15 amThe Current Clinical Conundrum: How Do WeDetermine the Ideal Management Strategy for aGiven Aneurysm Anatomy and PatientPhysiology?Michael Makaroun, MD

10:28 amHow to Manage Patients With Traumatic AorticInjury: Is There a Good Algorithmic ApproachThat Helps Us Decide What to Treat, When toTreat, and How to Treat?Daniel Sze, MD, PhD

10:41 amThe Spectrum of Anatomy and ClinicalManifestations of Penetrating Aortic Ulcer: WhatDictates When We Should Intervene?John F. Angle, MD

10:54 amAortic Intramural Hematoma: The PoorlyUnderstood Player in the Acute Aortic Syndrome:

What Do We Need to Appreciate About Its Role inThoracic Aortic Disease?David M. Williams, MD

11:07 amThe Clinical Catastrophe of Acute AorticDissection: Can We Define an IntegratedManagement Approach That Recognizes WhoBenefits Most From Particular TherapeuticOptions?Peter Mossop, MD

11:20 amWhy Do We Treat Chronic Aortic Dissection andWhat Determines When to Intervene and How?Johannes Lammer, MD

11:23 amComplications of Emerging EndovascularTherapies: What Do You and Your Patient Needto Know?Jon Matsumura, MD

11:36 amQ&A

10:00 am–12:00 pmPeripheral Vascular Imaging (CC)Room: 6ABC

Coordinator/Moderator: Bart L. Dolmatch, MD

Objectives—At the end of this session, thelearner should be able to:

1. Describe the use of multidector CT in the diag-nosis of venous thromboembolic disease

2. Outline the use of newer MRA sequences andtechniques for delineation of peripheral arterialdisease

3. Describe the use of CTA vs. MRA imaging fortreatment planning and follow up imaging ofPAD

10:00 amIntroductionBart L. Dolmatch, MD

10:05 amNIVLJames F. Benenati, MD

10:25 amQ&A

10:30 amMRABarry Stein, MD

10:50 amQ&A

10:55 amCTABart L. Dolmatch, MD

FRIDAY

P3

11:15 amQ&A

11:20 amCase Studies

1:15 pm–3:15 pmOncologic Interventions: Kidney (CC)Room: 6ABC

Coordinator/Moderator: Debra Ann Gervais, MD

1:15 pmSporadic Renal Cell Carcinoma: What You Needto Know About Epidemiology, Tumor Biology,Staging, and TreatmentTimothy W.I. Clark, MD

1:30 pmHereditary and Familial Renal Cell Carcinoma:Natural History and Integration of Laparoscopicand Percutaneous Ablation into TreatmentBradford Johns Wood, MD

1:45 pmPercutaneous Image Guided Cryoablation:ResultsStephen B. Solomon, MD

2:00 pmPercutaneous Image Guided RF Ablation: ResultsWilliam Smith-Mayo, MD

2:15 pmTranscatheter Arterial Embolization of Renal CellCarcinomaKamran Ahrar, MD

2:30 pmComplications of Percutaneous Image GuidedAblation and Techniques to Avoid ThemPeter R. Mueller, MD

2:45 pmImaging Challenges after Image Guided RenalTumor AblationDebra Ann Gervais, MD

3:00 pmQ&A

1:15 pm–3:15 pmAbdominal Aortic Aneurysms (CC)Room: 2AB

Coordinator/Moderator: John A. Kaufman, MD

Objectives—At the end of this session, thelearner should be able to:

1. Define a follow-up program for patients withAAA

2. Describe the current reported outcomes withEVAR

3. Compare the clinical applications of conven-tional and fenestrated/branched endografts

4. Summarize the different approaches to treatingendoleaks

5. Discuss the treatment of small AAA

1:15 pmSurveillance and Management of the AAAPatient in an IR Clinical PracticeJames L. Swischuk, MD

1:30 pmEVAR: The Data You Need to KnowJohannes Lammer, MD

1:45 pmFenestrated and Branched Grafts: Niche Cases orthe General Rule?Roy Greenberg, MD

2:00 pmFollow-up: CT, MRI, US, Plain Film, PressureSensing, or What?John A. Kaufman, MD

2:15 pmPost-EVAR Interventions: How I ApproachEndoleaksMatthew A. Mauro, MD

2:30 pmSmall Aneurysms: Management in 2010Barry T. Katzen, MD

1:15 pm–3:15 pmCarotid Interventions (CC)Room: 6E

Coordinator/Moderator: Tony P. Smith, MD

Objectives—At the end of this session, thelearner should be able to:

1. Demonstrate the clinical evaluation of carotidartery disease as it applies to stenting

2. Evaluate and employ pre- and post-proceduralpatient evaluation and therapies

3. Recognize the most appropriate treatment ofcarotid artery disease in special situations in-cluding restenosis, octogenarians, and tandemlesions

4. Analyze the medical-legal implications of ca-rotid artery stenting

5. Assess the advantages and disadvantages of ca-rotid artery stenting in asymptomatic patients

1:15 pmClinical Care: Evaluation of Carotid DiseaseKyra Becker, MD

P4

1:30 pmImaging in the Post-stented CarotidMahmood K. Razavi, MD

1:42 pmIn Stent Stenosis: Treatment OptionsTony P. Smith, MD

1:54 pmPeri- and Post-procedural MedicationsH. Bob Smouse, MD

2:06 pmStenting in the Octogenarian: Why the Problems?Christopher Zylak, MD

2:18 pmDealing with Tandem LesionsTony P. Smith, MD

2:30 pmMalpractice Issues Related to Carotid StentingRobert L. Vogelzang, MD

2:42 pmDEBATE: Should We Stent (or Treat)Asymptomatic PatientsRodney D. Raabe, MDJames L. Swischuk, MD

3:00 pmQ&A

3:45 pm–6:00 pmRenal Salvage Vascular Interventions (PL)Room: 6ABC

Coordinator/Moderator: Alan H. Matsumoto, MD

Objectives—At the end of this session, thelearner should be able to:

1. Describe the epidemiology of renovascular hy-pertension and related renal insufficiency

2. Report the results of renal stent revasculariza-tion for potential improvement or preservationof renal function

3. Define the controversies in the use of endovas-cular tools for reducing procedural risks in renalrevascularization

3:45 pmNatural History of Renal Artery Stenosis andPredictors of Clinical Significance When PresentStephen Chas Textor, MD

4:00 pmGold Medal PresentationJulio C. Palmaz, MD

4:15 pmImaging Evaluation and Correlation WithClinical SignificanceKlaus D. Hagspiel, MD

4:30 pmResults of PTRA/Stenting and Predictors ofRestenosisAlan H. Matsumoto, MD

4:45 pmDEBATE: Embolic Protection in Renal Arteries:Sham or Save?Timothy P. Murphy, MDThomas Sos, MD

5:00 pmMinimizing Contrast-Induced NephropathyDavid W. Hunter, MD

5:15 pmManaging Patients Post-InterventionStephen Chas Textor, MD

5:30 pmCORAL UpdateTimothy P. Murphy, MD

5:35 pmTreatment of Asymptomatic Renal Artery Stenosis:Dollars vs. Common CentsThomas Sos, MD

5:40 pmQ&A

FRIDAY

P5